Terms: = Liver cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Treatment
75 results:
1. Exosomal lncRNA HEIH, an essential communicator for hepatocellular carcinoma cells and macrophage M2 polarization through the miR-98-5p/STAT3 axis.
Ai JH; Wen YZ; Dai SJ; Zhang LD; Huang ZJ; Shi J
J Biochem Mol Toxicol; 2024 Apr; 38(4):e23686. PubMed ID: 38549433
[TBL] [Abstract] [Full Text] [Related]
2. Pharmacology and pharmacokinetics of tazemetostat.
Orleni M; Beumer JH
Cancer Chemother Pharmacol; 2024 May; 93(5):509-517. PubMed ID: 38520556
[TBL] [Abstract] [Full Text] [Related]
3. ezh2 is a key component of hepatoblastoma tumor cell growth.
Glaser K; Schepers EJ; Zwolshen HM; Lake CM; Timchenko NA; Karns RA; Cairo S; Geller JI; Tiao GM; Bondoc AJ
Pediatr Blood Cancer; 2024 Feb; 71(2):e30774. PubMed ID: 37990130
[TBL] [Abstract] [Full Text] [Related]
4. EMT-related gene risk model establishment for prognosis and drug treatment efficiency prediction in hepatocellular carcinoma.
Gao X; Yang C; Li H; Shao L; Wang M; Su R
Sci Rep; 2023 Nov; 13(1):20380. PubMed ID: 37990105
[TBL] [Abstract] [Full Text] [Related]
5. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma.
Ding D; Wang D; Qin Y
Medicine (Baltimore); 2023 Nov; 102(46):e36190. PubMed ID: 37986299
[TBL] [Abstract] [Full Text] [Related]
6. Tazemetostat decreases β-catenin and CD13 protein expression in HEPG-2 and Hepatitis B virus-transfected HEPG-2 with decreased cell viability.
Amin MN; El-Far YM; El-Mowafy M; Elgaml A
Clin Epigenetics; 2023 Nov; 15(1):180. PubMed ID: 37941056
[TBL] [Abstract] [Full Text] [Related]
7. Targeting WNT/β-Catenin via Modulating ezh2 Function: A New Chapter in the treatment of β-Catenin Mutant Hepatocellular Carcinoma?
Hung MH; Wang XW
Cancer Res; 2023 Nov; 83(21):3498-3500. PubMed ID: 37747420
[TBL] [Abstract] [Full Text] [Related]
8. FGFR4 and ezh2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling.
Yang Y; Zhang Y; Cao J; Su Z; Li F; Zhang P; Zhang B; Liu R; Zhang L; Xie J; Li J; Zhang J; Chen X; Hong A
J Exp Clin Cancer Res; 2023 Apr; 42(1):96. PubMed ID: 37085881
[TBL] [Abstract] [Full Text] [Related]
9. Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis.
Liao X; Li Z; Zheng H; Qian W; Zhang S; Chen S; Li X; Tang M; Xu Y; Yu R; Li M; Song L; Li J
Mol Cancer Res; 2023 Jul; 21(7):648-663. PubMed ID: 36961398
[TBL] [Abstract] [Full Text] [Related]
10. CBX2-mediated suppression of SIAH2 triggers WNK1 accumulations to promote glycolysis in hepatocellular carcinoma.
Xu Z; Wu Y; Yang M; Wei H; Pu J
Exp Cell Res; 2023 May; 426(1):113513. PubMed ID: 36780970
[TBL] [Abstract] [Full Text] [Related]
11. ezh2 Promotes Cholangiocarcinoma Development and Progression through Histone Methylation and microRNA-Mediated Down-Regulation of Tumor Suppressor Genes.
Zhang J; Chen W; Ma W; Han C; Song K; Kwon H; Wu T
Am J Pathol; 2022 Dec; 192(12):1712-1724. PubMed ID: 36456043
[TBL] [Abstract] [Full Text] [Related]
12. Down-regulation of BMAL1 by MiR-494-3p Promotes Hepatocellular Carcinoma Growth and Metastasis by Increasing GPAM-mediated Lipid Biosynthesis.
Yang Y; Yang T; Zhao Z; Zhang H; Yuan P; Wang G; Zhao Z; An J; Lyu Z; Xing J; Li J
Int J Biol Sci; 2022; 18(16):6129-6144. PubMed ID: 36439870
[TBL] [Abstract] [Full Text] [Related]
13. Construction of a Novel Oxidative Stress Response-Related Gene Signature for Predicting the Prognosis and Therapeutic Responses in Hepatocellular Carcinoma.
Hong J; Cai X
Dis Markers; 2022; 2022():6201987. PubMed ID: 36133439
[TBL] [Abstract] [Full Text] [Related]
14. DNMT and ezh2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.
Zhang L; Li HT; Shereda R; Lu Q; Weisenberger DJ; O'Connell C; Machida K; An W; Lenz HJ; El-Khoueiry A; Jones PA; Liu M; Liang G
Cancer Lett; 2022 Nov; 548():215899. PubMed ID: 36087682
[TBL] [Abstract] [Full Text] [Related]
15. TGF-β1/Smad3 upregulates UCA1 to promote liver fibrosis through DKK1 and miR18a.
Yang Z; Zhang H; Yin M; Cheng Z; Jiang P; Feng M; Liu Z; Liao B
J Mol Med (Berl); 2022 Oct; 100(10):1465-1478. PubMed ID: 36001113
[TBL] [Abstract] [Full Text] [Related]
16. Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib.
Salani F; Latarani M; Casadei-Gardini A; Gangadharannambiar P; Fornaro L; Vivaldi C; Pecora I; Massa V; Marisi G; Canale M; Ulivi P; Scartozzi M; Eccleston M; Masi G; Crea F
Epigenomics; 2022 May; 14(9):507-517. PubMed ID: 35473355
[TBL] [Abstract] [Full Text] [Related]
17. Transcriptional suppression of Dicer by HOXB-AS3/ezh2 complex dictates sorafenib resistance and cancer stemness.
Tseng CF; Chen LT; Wang HD; Liu YH; Shiah SG
Cancer Sci; 2022 May; 113(5):1601-1612. PubMed ID: 35253323
[TBL] [Abstract] [Full Text] [Related]
18. ezh2-mediated H3K27me3 promotes autoimmune hepatitis progression by regulating macrophage polarization.
Chi G; Pei JH; Li XQ
Int Immunopharmacol; 2022 May; 106():108612. PubMed ID: 35193055
[TBL] [Abstract] [Full Text] [Related]
19. EBF3 reactivation by inhibiting the EGR1/ezh2/HDAC9 complex promotes metastasis via transcriptionally enhancing vimentin in nasopharyngeal carcinoma.
Ding S; Wang X; Lv D; Tao Y; Liu S; Chen C; Huang Z; Zheng S; Wei Y; Kang T; Xia Y
Cancer Lett; 2022 Feb; 527():49-65. PubMed ID: 34906623
[TBL] [Abstract] [Full Text] [Related]
20. EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma.
Kusakabe Y; Chiba T; Oshima M; Koide S; Rizq O; Aoyama K; Ao J; Kaneko T; Kanzaki H; Kanayama K; Maeda T; Saito T; Nakagawa R; Kobayashi K; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Nakamoto S; Yasui S; Mikata R; Muroyama R; Kanda T; Maruyama H; Kato J; Mimura N; Ma A; Jin J; Zen Y; Otsuka M; Kaneda A; Iwama A; Kato N
Sci Rep; 2021 Nov; 11(1):21396. PubMed ID: 34725436
[TBL] [Abstract] [Full Text] [Related]
[Next]
